SCHEMBL4090887

SCHEMBL4090887

FC(F)(F)Oc1ccc(-c2nc(N3CCCCC3)c3ccccc3n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.70
GBA1 P04062 2/20 0.67
TP53 P04637 1/20 0.65
LMNA P02545 3/20 0.64
MAPT P10636 2/20 0.64
TSHR P16473 4/20 0.62
USP2 O75604 2/20 0.62
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
MAPK1 P28482 2/20 0.57
HSD17B10 Q99714 2/20 0.57
ALDH1A1 P00352 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HIF1A Q16665 1/20 0.56
SIRT1 Q96EB6 1/20 0.55
TLR7 Q9NYK1 1/20 0.54
ABCG2 Q9UNQ0 1/20 0.54
RAB9A P51151 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
METAP1 P53582 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4085184 0.99 ACP1 (0.69) ACP1GBA1TP53LMNAMAPT
SCHEMBL4088950 0.88 HTT (0.65) ACP1GBA1TP53LMNATSHR
SCHEMBL4090419 0.88 GBA1 (0.68) GBA1TP53LMNAMAPTTSHR
SCHEMBL4090807 0.84 ACP1 (0.75) ACP1GBA1TP53LMNAMAPT
SCHEMBL1084122 0.83 ACP1 (1.00) ACP1TP53LMNAMAPTTSHR
SCHEMBL1083859 0.83 ACP1 (1.00) ACP1TP53LMNAMAPTTSHR
SCHEMBL4095137 0.83 ACP1 (0.74) ACP1GBA1TP53LMNAMAPT
SCHEMBL1084295 0.82 ACP1 (0.81) ACP1GBA1TP53LMNAMAPT
SCHEMBL23948080 0.82 GBA1 (0.63) ACP1GBA1TP53TSHRKMT2A
SCHEMBL4089260 0.82 ACP1 (1.00) ACP1TP53LMNAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 ACP1 3504/4885GBA1 2059/4885TP53 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.